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Summary The anti-tumour actvity of methyl-p-cyckxdextrin (MEBCD), a cydic oligosaccharide known for its interaction with the plasma
membrane, was investigated in vitro and in vivo and compared with that of doxorubicin (DOX) in the human tumour models MCF7 breast
carcinoma and A2780 ovanan carcinoma. In vitro proliferation was assessed using the MTT assay. In vivo studies were carmied out using
xenografted Swiss nude mice injected weeldy i.p. with MEBCD at 300 or 800 mg kg-, or DOX at 2 mg kg-', durng 2 months. Undrer these
conditions, MEBCD was active against MCF7 and A2780 cell lines and tumour xenografts. For each tumour model, the tumoral volume of the
xenografted mice treated with MEBCD was at leasttwofold reduced compared wit the control group. In the MCF7 model, MEBCD (800 mg kg-')
was more active than DOX (2 mg kg-1). After 56 days of treatnent with MEBCD, no toxicologically meaningful differences were observed in
macroscopic and microscopic parameters compared with controls. The accumulation of MEBCD in normal and tumourtssues was also assessed
using a chromatographic method. Results indicated that after a single injection of MEBCD, tumour, liver and kidneys accumulated the highest
concentrations of MEBCD. These results provided a basis for the potental therapeutic application of MEBCD in cancertherapy.
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Toxicitv and drug resistance are probably the major mechanisms
for failure oftherapy in cancer. To oxvercome these problems. there
is a need to develop antiproliferatiVe agents actix e on other
cellular targets. such as the cell membrane.
Cvclodextrins (CDs) are known for modifying, the physicophar-
maceutical properties of various drugs and components through
inclusion complex formation (-Hiravama and Uekama. 1987:
Allegre and Deratani. 1994: Bressolle et al. 1996). The inclusion
of the drug may have several advantages. such as an increased
aqueous solubilitx and stabilitv or a reduction of unwanted side
effects (Szetlji. 1994). However. CDs should not be regarded as
simple excipients or solubility enhancers because the formation of
inclusion complexes might occur with some biological compo-
nents such as cholesterol and lipid components of the biological
and cellular membrane. leading to an enhanced permeability to
various molecules (Cho et al. 1995: Hovgaard and Brondsted.
1995: Krishnamoorthy et al. 1995). Thus. we have previously
shown that. at non-cvtotoxic concentrations. methyl-[-Bcyclodex-
trin (MEBCD) was able to potentiate the in vitro anti-tumoral
actix itv ofdoxorubicin (DOX) in several parental sensitix e cancer
cell lines and their multidrug-resistant sublines. but x-e also
showed that the action of MEBCD on the cell was independent of
that of DOX (Grosse et al. 1997a. 1998). Several studies confirm
that some CDs have their own cellular activiity in terms of interac-
tion with the plasma membrane. permeabilization or haemolytic
activitv (Szejtli et al. 1986: Castelli et al. 1989; Kilsdonk et al.
1995). Only a fexx in vivo studies concerning the effect and the
toxicitx- of CDs injected directlx in human or animal organisms
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hax-e been performed. x-hereas there are no reports on the use of
CDs in cancer (Bellrinner et al. 1995). The toxicolooical effects
appeared to be related to the structure of the CD. Non-substituted
CDs were found to be highly toxic for the kidneys (Brexster et al.
1990: Bellringer et al. 1995). whereas the toxicitv of substituted
CDs varies with the degree and the nature of the substitution
(Frijlink et al. 1990. 1991: Giordano. 1991: Flourie et al. 1993).
MEBCD is considered an interesting candidate for experimental
cancer treatment because of its relatively low toxicity. contrary to
di- and tri-methyl-$-CD. and its demonstrated activitx in cancer
cell lines.
In this report. x e present in X itro growth-inhibitory data
obtained for MEBCD in two human carcinoma cell lines (MCF7
and A2780) and comparative data on their in xixo anti-tumour
activitx in human xenoggrafted mice. In addition. xxe investigated
the murine tumoral and tissular distribution ofMEBCD.
MATERIALS AND METHODS
Drugs and chemicals
MEBCD (FFigure 1). tetrazolium dye (MTT) and phosphate-
buffered saline (PBS: Sigma. St Quentin Fallaxier. France).
RPMI-1640 medium. fetal calf serum (FCS) and trypsin-EDTA
(Gibco. Cergy Pontoise. France) were used in this study. All other
reagents were of analytical grade and xxwere obtained from Carlo
Erba (Milan. Italv) or Prolabo (Paris. France).
MEBCD sensitivity in vitro
The human breast adenocarcinoma cell line MCF7 (Soule et al.
1973: Minnaugh et al. 1991 ) was obtained from the American Type
Culture Collection (Rockxille. MD. USA). The human ovarian
adenocarcinoma A-780 was a kind gift from Dr Canal (Centre
11651166 PYGrosseetal
Claudius Regaud, Toulouse. France). Exponentially growing cells
were used for experinments and all cells were free of mycoplasma.
Cells were maintained as suspension cultures at 37°C in a humidi-
fied atmosphere containing 5% carbon dioxide in RPMI-1640
medium supplemented with 10% FCS, antibiotics and glutamnine.
The viability of the cells was assessed by their ability to exclude
0.5% tiypan blue dye. Cell density in culture flasks was determined
by a Coulter counter (Model ZI, Hialeah, FL, USA). To determine
the cytotoxic effect of MIEBCD, preconfluent cells from stock
cultures (106 cells ml) were treated as follows: adherent tumour
MCF7 and A2780 cells were detached with typsin-EDTA
(0.25:0.02% w/v) in PBS, washed twice with PBS and resuspended
in complete culture medium to obtain single-cell suspension. Cells
were counted and then seeded at a final density of6 x 103 cells per
well in 96-well microtitre plates in a final volume of 100g1. The
cells were then allowed to attach for 24 h at 370C. Afterreconstitu-
tion in purified water, MEBCD was diluted in culture medium and
was added in various concentrations to wells (O.1-1O mM), then
cells were incubated for 96 h at 37°C (atmosphere containing 5k
carbondioxide). Thecytotoxicity ofMEBCD wasquantifiedby the
MTN assay (Alley et al, 1988; Heo et al, 1990; Colangelo et al,
1992). Metabolic reduction of the tetrazolium salt MTI [3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide] leads to
fonnation of MTT-formazan. MUT (50 1 of 1 mg ml-' in sterile
PBS) was added to each well and plates were incubated for 4 h at
37°C. Blue formazan crystals formed were dissolved in a mixture
of isopropanol and hydrochloric acid 1 M (96:4 vlv). The plates
were then gently agitated for 10 min and the absorbance measured
at 570 nm on a microculture plate reader (Dynatech MR5000,
France). The IC 0 values were defined as the concentration ofdrug
resulting in 50% survival of the eated cells compared with
controls and were calculated using a program implemented on
EXCEL 5.0 software. For each assay, three different experiments
were performed in triplicate.
Detemination of MEBCD LD.0 in mice
MEBCD LD5 was determined using female Swiss mice aged S
weeks and weighing 22-28 g. Seven groups ofsix mice (MEBCD
at 100, 200, 500, 1000, 1500, 2000 and 3000mg kg-') were
injected i.p. weekly for 4 weeks and were then monitored over a
span of2 months.
MEBCD sensitivity in vivo
MCF7 and A2780 cells diluted in RPMI-1640 medium (107 cells
in 250 1) were inoculated subcutaneously into the flank area of
female nude congenic athymic mice of Swiss strains homozygous
for the nude gene (nu+/nu+). All mice were purchased from Iffa
Credo (Lyon, France). They were aged 5 weeks and weighed
20-22 g at the start of experiments. These were conducted in
accordance with the protocols published by the European
Organization for Research and Treatment of Cancer (EORTC)
members (Geran et al, 1972). Mice were kept under sterile condi-
tions and were given sterilized food and water. As the MCF7
human cancer cell line requires exogenous oestrogen for efficient
tumorigenicity, the mice intended for MCF7 xenografts were,
therefore, aseptically implanted subcutaneously in the
intrascapular region with 0.72 mg 60-day release 17.oestradiol
pellets (Innovative Reseach ofAmerica, Toledo. OH, USA) 2 days
before injection of tumour cells. The A2780 tumour cell line is
Table 1 Mean tmour volume reduction ratio observed after 8 weeks of
treatnent (ANOVA P-value)
Tumour model MEBCOIcontrol DOXlcontrol MEBCD/DOX
MCF7 2.2 (<0.01) 1.6 (<0.02) 1.4 (<0.05)
A2780 2.5 (<0.01) ND ND
ND: not done.
oestrogen independent and does not respond to oestradiol stimula-
tion of proliferation in vivo. The growth of MCF7 and A2780
xenografted tumour was monitored every 7 days by measuring the
tumour with calipers in three dimensions following the formula
length x width x thickness x m16 as described for murine solid
tumours (Tomayko and Reynolds, 1989).
Fourdifferent groups ofsix mice were used for MCF7 tumours:
normal saline (0.9%) as control group, MEBCD in sterile normal
saline (0.9%) at 300 or 800 mg kg-', and DOX at 2 mg kg-' as a
treatment reference group. Experiments were repeated twice. For
A2780 tumours, only two groups were carried out (control and
MEBCD at 800 mg kg-'). Drugs or normal saline (250 p1) were
injected i.p., weekly, starting 7 days after inoculation of tumour
cells, a time when the solid tumours were just palpable and
progressed for a total of eight treatments. Tumour response to
MEBCD was assessed by comparing the median tumour volume
ofeach MEBCD-treated group with that ofthe control group.
MEBCD tumoral and tissular distribution
To determine the relative concentrations ofMEBCD in MCF7 and
A2780 xenografted mice and to contrast tumour drug levels with
host tissues, MEBCD at 800 mg kg-' was administered i.p. to
mice. Three hours later, the animals were killed by cervical dislo-
cation and tumours, liver, kidneys, lungs, small intestine and brain
were removed, washed in PBS, weighed and frozen for later
processing. After thawing, tumours and tissues (0.5 g) were quar-
tered and homogenized in 1 ml of purified water with a Tissue
Tearor homogenizer (Biospec Products, Bartlesville, OK, USA).
Samples were then treated as described in a previous paper
(Grosse et al, 1997b). Briefly, after addition of20 p1 ofpotassium
hydroxide (5 M), alkaline extraction of MEBCD was carried out
using 3 ml ofchloroform. The lowerorganic phase was transferred
to a fresh tube and evaporated under nitrogen stream. The residue
was then reconstituted into 200 1 ofmobile phase consisting ofa
mixture of water and methanol (98:2 v/v) containing 10-4 M of 1-
naphthol as a fluorophore and injected onto the analytical column.
The detection ofMEBCD is based on the enhancement offluores-
cence of l-naphthol caused by its complexation in the cavity of
the CD. The flow rate was 1 ml min-'. A stainless-steel column
(300 x 7.5 mm i.dc) packed with exclusion gel TSK 3000 SW
was used and fluorimetric detection was performed at excitation
and emission wavelengths of 290 and 360 nm respectively.
Experiments were carried out in triplicate.
Statistical analysis
In each treated group. data were analysed by ANOVA one-way
tests (compared with control values) and differences between
mean values at P < 0.05 were considered to be significant.
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Figure 1 Structural formula of methyl-)-cyclodextrin (MEBCD)
RESULTS
In vitro cytotoxicity of MEBCD
Figure 2 shows MCF7 and A2780 cellular proliferation curves in
relation to MEBCD concentrations. These results showed that a
1001% inhibition of growth was achieved at concentrations of
MEBCD > 2 nvm. The IC, value averaged 1.49 and 1.55 mnm for
MCF7 and A2780 cell lines respectively. For concentrations from
0.1 to 1 nmLI. no significant cytotoxic activity was observed.
Determination of MEBCD LD50
MEBCD LD;,, was determined using doses ranging from 100 to
3000 mg kg-'. injected i.p. in Swiss mice. Injections were
performed exery week. during 1 month. Doses higher than
2000 mg kg-I were immediatelv lethal. Over a span of 1 month. the
LDc dose was found to be close to 1500 mg kg-' week-'. for a
cumulative dose of6000 mg ka-'. No lethality was found in groups
treated with MEBCD at 100. 200. 500. and 1000 mg kg-' week-'.
Three. five and six deaths were observed in groups treated with
1500, 2000 and 3000 mg kg-' week-' respectively. Doses lower
than 1000 mg kg-' week-' appeared to be non-toxic after four
injections ofMEBCD and for 2 further months ofmonitoring.
Antiproliferative effect of MEBCD in human xenografts
The anti-tumour activity of MEBCD has been checked in nude
mice xenografted with an oestrogen-dependent human breast carci-
noma MCF7 model. Tumour volume of mice injected i.p. weeklx
either with normal saline (control) or drugs (MEBCD at 300 or
800 mgy kg-' or DOX at 2 mg kg-' as a reference treatment) were
estimated each week during 2 months. Tumour growth curses are
presented in Figure 3A. Experiments on the four groups ofsix mice
were carried out in duplicate and show. after 5 weeks of treatment.
a clear reduction of the tumour x-olume in mice receixing MEBCD
at 300 or 800mg kg-1. compared with control. The antiproliferative
activity of MEBCD was statistically higher than the DOX one. To
confirm these data in a non-oestrogen-dependent tumour model.
100 200 500 1000 2000 5000 10000
MEBCD (gm)
Figure 2 Survival of MCF7 (-) and A2780 (_) cells treated with MEBCD at
vanous concentrations. Each point represents the mean value for three
different experiments performed in triplicate. Error bars represent s.d.
assays were carred out using ovarian A2780 tumour-xenografted
mice treated with either MEBCD at 800 mg kg--' ornormal saline as
control (Figure 3B). Results obtained are similar to those in the
MCF7 model. Results are expressed as the mean tumour volume
reduction ratio observed in the differentgroups and are presented in
Table 1. After each of the eight injections. mice treated with
MEBCD and controls were in good form and did not lose any body
weight. No lethality was obsersed in these two groups. At the end
ofthe studies. the autopsies of mice treated with MEBCD revealed
no macroscopic anomalies compared with the control group. Mice
treated for more than 6 weeks with DOX exhibited body weiaht
losses exceedinr 25% and cumulative toxicity became lethal after
sexen treatments (4 deaths out of 18 mice).
Tumour and normal tissues determination of MEBCD
Tumour and normal tissues determination of MEBCD was
performed in mice undergoing a single dose i.p. of MEBCD at
800 mg kg-'. using a high-performance liquid chromatography
(HPLC) method. Assay parameters are defined as follow%s: limit of
quantitation of MEBCD was 0.5 Ixm. the method of quantitation
w-as based on the MEBCD vs internal standard (daunorubicin)
peak area ratios and the retention times were 4.8 and 11.1 min for
daunorubicin and MEBCD respectixely. Linearity of the method
was statisticallv confirmed o-er a range of concentrations of
1-100 -iM. Results are shown in Figure 4. Intratissular MEBCD
concentrations are expressed in nmol g-' of tissue. After 3 hours.
significant amounts of MEBCD were found in tumour. kidnevs.
small intestine and liver. Concentrations in lunas and muscle were
almost undetectable.
DISCUSSION
In cancer chemotherapy. there is a need to develop new drugs. This
mav involve identifying and exploiting novel molecular features of
cancer cells. One possible new target may be the cell membrane
that is the potential site for some new antineoplastic agents like
miltefosine (Arancia and Donelli. 1991: Stekar et al. 1995).
Likewise. methylated CDs are cyclic oligosaccharides that have
been shown to interact with lipid components of the biological
membranes. modifying their fluidity and their permeability. In
previous studies. we described the potentiation of the cytotoxic
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Figure 3 Tumour growth curves of s.c. MCF 7 (A) or
in nude mice treated with doses of 800 mg kg-, MEBCI
MEBCD (1), 2 mg kg-' DOX (A) or normal saline as a
volume was estmated as descrbed in Materials and rr
MCF7 xenografts are the means of two expenments ca
independently on six mice. Data for A2780 xenografts
experiment carried out on six mice. Error bars represe
P< 0.02; -P < 0.01 (ANOVA test)
actixity of some antineoplastic agents induce(
with non-cytotoxic concentrations of MEBCI
cell lines (Grosse et al. 1997a. 1998). In this st
demonstrated also a marked anti-tumour a
human breast and ovarian carcinoma cancer cel
tions higher than 1.0 mxi (IC< at about 1.5 m-v
curves indicate there was no growth inhibition
trations up to 1.0 mms. whereas a 100% inhibi
achieved at concentrations higher than 2.0 m
activity in vivo. athyrmic nude mice have been
oestrogen-dependent human breast carcinoma
treated every week with MEBCD. DOX or no
weeks oftreatment, tumour volume in mice tn
at 300 and 800 mg kg' was statistically redu
control. After eight injections. this reduction c
control tumour volume. Moreover. the most n
that the antiproliferative activity of MEBCD O
least equal to the DOX one. a reference a
56 Figure 4 Relative concentratons of MEBCD in various tissues and tumour
xenografts of mice (n = 3). Analysis conditions were as described in Materials
and methods
commonlv used in chemotherapy regimens against most carci-
nomas (Muggia and Green. 1991). Similar results were obtained
using the ovarian A-780 tumour model which does not require the
inoculation of an exogenous oestradiol pellet. Indeed. tumour
.-! - ,rowth curves of control and MEBCD-treated groups showed
similar features. The tumour reduction ratio observed with
MEBCD was in the same order of magnitude as in the MCF7
tumour model. indicating that the anti-tumour activity of MEBCD
is independent of the oestradiol exogenous supplementation.
Throughout the study. mice treated with MEBCD and controls
were always in good form and showed no behavioural or physical
changes such as body weight losses. both compared with the start
42 49 56 ofthe study. No lethality was obsern ed in these tx o groups. At the
end ofthe studies. mice treated with MEBCD andrapidly autopsied
A2780 (B) xenografts revealed no macroscopic anomalies. and organ samples were iden-
D (M). 300 mg kg- tical to those ofthe control group. In contrast. mice treated for more
ontrol ( ). The tumour than 6 weeks with DOX showed body weight losses exceeding
iefthods. Data for t
arried out 25% and cumulative toxicity became lethal after seven treatments.
are themeans of one As MEBCD showed a clear antiproliferative effect in MCF7
nt s.e. 'P < 0.05; and A2780 xenografts. we can assume that MEBCD is distributed
in the tumour tissue. To confirm this point. the distribution of
MEBCD in several organs was investigated 3 hours after drug
administration. usinga an HPLC method. Significant levels of
J by the association MEBCD were detected in small intestine. liver. kidneys and
D in several cancer tumour but higher concentrations were found in kidneys and
Ludy. MEBCD alone tumour xenografts. The accumulation in kidneys could be related
ctivity against two to the renal elimination of other substituted CDs after an intra-
11 lines at concentra- venous administration. reported by several authors (Brewster et al.
M). The proliferation 1990: Frijlink et al. 1991: Giordano. 1991). As 0.5 ml ofplasma is
at MEBCD concen- required for the HPLC method. MEBCD plasma levels were not
ition of growth was determined in mice. In contrast. the tropism of MEBCD for the
um. To confirm this xenografted tumour is proven by its tumoral accumulation. which
inoculated with the is undoubtedly linked to the tumour growth inhibition observed.
MCF7 model and This antiproliferative activity should be due to the great affinity
ormal saline. After 5 of MEBCD for cell membrane lipid components. particularly
eated with MEBCD cholesterol. which play a major role in the structure and the func-
iced compared with tioning of the cell membrane. Thus. MEBCD is able to include
ivertook 50% of the cholesterol in its cavity and then to remove it from the cell
-emarkable aspect is membranes (Castelli et al. 1989: Szejtli et al. 1986: Cho et al.
800 mg kg'l) was at 1995: Hovgaard and Brondsted. 1995: Kilsdonk et al. 1995:
mtineoplastic agent Krishnamoorthy et al. 1995).
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Plasmatic and tissular pharmacokinetics of MEBCD and DOX.
alone or in combination, are actually being performed in rabbit to
gather further knowledge on biological comportment of MEBCD.
Moreover, assays will be carried out to investigate the antiprolifer-
ative activity of MEBCD in cell lines and xenograft tumour
models overexpressing the MDR phenotype.
The cytotoxicity against two human carcinoma cell lines, the
inhibition of MCF7 and A2780 xenografted tumour growth
comparable to that obtained with DOX, and the apparent innocuity
of doses injected in xenografted nude mice make of MEBCD.
alone or in combination with other antineoplastic agents, a poten-
tial candidate for cancer therapy.
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